EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
Phase 3negativeNegative
AI Analysis
Summary
EyePoint's Phase 3 trial for an age-related macular degeneration treatment failed, resulting in a 70% stock decline. The clinical miss represents a setback in the company's efforts to reduce treatment burden for AMD patients.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 clinical trial failed
Importance:8/10
Sentiment:
-0.95
Phase_3_failureAMDage-related_macular_degenerationstock_decline
Related Companies
Read the original article
Published by BioSpace on August 17, 2026 2:40 PM